Skip to main content
X

The information contained on this global HIPRA website is not intended for audiences in all countries.

General, scientific or technical information about HIPRA products or services is not intended for commercial promotion.

For specific information on the products or services available in your country, please filter by the corresponding country.

bimervax

BIMERVAX®, emulsion for injection

TriangleBIMERVAX®, COVID-19 adjuvanted recombinant protein vaccine. 

 

Marketing authorization in the European Union since 30 March 2023 and in the United Kingdom since 31 July 2023.

 

Update date: 18/06/24

 

The use of this vaccine should be according official recommendations.

PRESENTATIONS of BIMERVAX emulsion for injection:

· Multidose vial which contains 10 doses of 0.5 mL

· Single dose vial which contains 1-dose of 0.5 Ml  

PRESCRIPTION AND DISPENSING CONDITIONS. Medicinal product subject to medical prescription. Dispensing should be conducted in health care sites.

PRICE (PVL):  . Not included in the pharmaceutical provision of the National Health System due to the fact that the acquisition of this vaccine against SARS-CoV-2 is being carried out in the European Union by means of a centralised European purchasing procedure, conducted by the European Commission on behalf of the Member States.

 

 

TriangleThis medicine is subject to additional monitoring, which will expedite the detection of new safety information. Healthcare professionals are invited to report suspected adverse reactions.